HRP20230695T1 - Povećanje prinosa virusu sličnih čestica u biljkama - Google Patents
Povećanje prinosa virusu sličnih čestica u biljkama Download PDFInfo
- Publication number
- HRP20230695T1 HRP20230695T1 HRP20230695TT HRP20230695T HRP20230695T1 HR P20230695 T1 HRP20230695 T1 HR P20230695T1 HR P20230695T T HRP20230695T T HR P20230695TT HR P20230695 T HRP20230695 T HR P20230695T HR P20230695 T1 HRP20230695 T1 HR P20230695T1
- Authority
- HR
- Croatia
- Prior art keywords
- plant
- seq
- influenza
- protein
- vlp
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims 3
- 241000196324 Embryophyta Species 0.000 claims 18
- 238000000034 method Methods 0.000 claims 17
- 101710154606 Hemagglutinin Proteins 0.000 claims 15
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 15
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 15
- 101710176177 Protein A56 Proteins 0.000 claims 15
- 239000000185 hemagglutinin Substances 0.000 claims 14
- 206010022000 influenza Diseases 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 239000002773 nucleotide Substances 0.000 claims 7
- 125000003729 nucleotide group Chemical group 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 230000009466 transformation Effects 0.000 claims 6
- 108091006146 Channels Proteins 0.000 claims 5
- 102000034573 Channels Human genes 0.000 claims 4
- 241000723607 Comovirus Species 0.000 claims 4
- 208000037797 influenza A Diseases 0.000 claims 4
- 230000001105 regulatory effect Effects 0.000 claims 4
- 241000702463 Geminiviridae Species 0.000 claims 3
- 208000037798 influenza B Diseases 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 241000577998 Bean yellow dwarf virus Species 0.000 claims 2
- 241000723655 Cowpea mosaic virus Species 0.000 claims 2
- 108091029795 Intergenic region Proteins 0.000 claims 2
- 230000003321 amplification Effects 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 230000030279 gene silencing Effects 0.000 claims 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims 2
- 230000002797 proteolythic effect Effects 0.000 claims 2
- 108010042653 IgA receptor Proteins 0.000 claims 1
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 claims 1
- 108091023045 Untranslated Region Proteins 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 238000003306 harvesting Methods 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
- C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16223—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16251—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Claims (16)
1. Metoda proizvodnje virusu slične čestice (VLP) u biljci koja sadrži,
a) uvođenje transformacijom prve nukleinske kiseline koja sadrži prvu regulatornu regiju aktivnu u biljci i operativno povezanu s nukleotidnom sekvencom koja kodira protein hemaglutinina (HA) influence koji je odabran iz skupine koja se sastoji od B i H3 u biljku ili dio biljke,
b) uvođenje transformacijom druge nukleinske kiseline koja sadrži drugu regulatornu regiju aktivnu u biljci i operativno povezanu s nukleotidnom sekvencom koja kodira protein protonskog kanala koji je odabran iz skupine koja se sastoji od M2 i BM2, i
c) inkubaciju biljke ili dijela biljke za proizvodnju VLP-a.
2. Metoda prema patentnom zahtjevu 1, pri čemu metoda nadalje sadrži korak
d) žetve biljke i pročišćavanja VLP-a.
3. Metoda prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, pri čemu metoda sadrži uvođenje transformacijom treće nukleinske kiseline koja sadrži nukleotidnu sekvencu koja kodira supresor utišavanja.
4. Metoda prema patentnom zahtjevu 3, pri čemu je supresor utišavanja HcPro ili p19.
5. Metoda prema bilo kojem od patentnih zahtjeva 1 do 4, pri čemu je protein protonskog kanala odabran između influence A/Puerto Rico/8/1934 ili influence A/New Caledonia/20/1999 i/ili pri čemu protein protonskog kanala sadrži specifičnu sekvencu protonskog kanala HXXXW.
6. Metoda prema bilo kojem od patentnih zahtjeva 1 do 5, pri čemu je protein hemaglutinin (HA) influence protein HA0 i/ili pri čemu je influenca B HA od influence B/Brisbane/60/2008, B/Malaysia/2506/2004 ili B/Wisconsin/1/2010 i/ili pri čemu je influenca H3 od influence A/Perth/16/2009 ili od influence A/Victoria/361/2011.
7. Metoda prema bilo kojem od patentnih zahtjeva 1 do 6, pri čemu je izbrisana jedna ili više proteolitičkih petlji proteina B HA influence.
8. Metoda prema bilo kojem od patentnih zahtjeva 1 do 7, pri čemu nukleotidna sekvenca koja kodira protein hemaglutinina (HA) influence:
a) ima sekvencu koja je najmanje 70 % identična sekvenci koja je odabrana iz skupine koja se sastoji od SEQ ID NO:28, SEQ ID NO:51 i SEQ ID NO:61;
b) je kako je prikazano u najmanje jednom od SEQ ID NO:30, SEQ ID NO:54 i SEQ ID NO:64;
c) ima sekvencu koja je najmanje 70 % identična sekvenci koja je odabrana iz skupine koja se sastoji od SEQ ID NO:43 i podcrtanog dijela SEQ ID NO:57;
d) je kako je prikazano u najmanje jednom od SEQ ID NO:41 i SEQ ID NO:58;
e) ima sekvencu koja je najmanje 70 % identična sekvenci koja je odabrana iz skupine koja se sastoji od SEQ ID NO:23 i SEQ ID NO:46; i/ili
f) je kako je prikazano u najmanje jednom od SEQ ID NO:25 i SEQ ID NO:48.
9. Metoda prema bilo kojem od patentnih zahtjeva 1 do 8, pri čemu prva nukleinska kiselina sadrži prvu regulatornu regiju operativno povezanu s jednim ili više pojačivača komovirusa, nukleotidnu sekvencu koja kodira protein hemaglutinina (HA) influence, jedan ili više elementa amplifikacije geminivirusa, a treća nukleinska kiselina koja sadrži nukleotidnu sekvencu koja kodira replikazu geminivirusa uvodi se u biljku ili dio biljke.
10. Metoda prema patentnom zahtjevu 9, pri čemu je jedan ili više pojačivača komovirusa UTR komovirusa.
11. Metoda prema patentnom zahtjevu 10, pri čemu je UTR komovirusa UTR virusa mozaika kravljeg graška (CPMV).
12. Metoda prema bilo kojem od patentnih zahtjeva 9 do 11, pri čemu je jedan ili više elementa amplifikacije geminivirusa duga međugena regija virusa žute patuljavosti graha (BeYDV LIR) i kratka međugena regija virusa žute patuljavosti graha (BeYDV SIR).
13. Biljna tvar koja sadrži VLP proizveden metodom prema bilo kojem od patentnih zahtjeva 1 do 12, pri čemu VLP sadrži protein hemaglutinina (HA) influence odabran iz skupine koja se sastoji od B i H3, a biljna tvar nadalje sadrži protein protonskog kanala odabran iz skupine koja se sastoji od M2 i BM2.
14. Dodatak prehrani koji sadrži biljnu tvar prema patentnom zahtjevu 13.
15. Metoda proizvodnje virusu slične čestice (VLP) u biljci koja sadrži,
a) uvođenje transformacijom prve nukleinske kiseline koja sadrži prvu regulatornu regiju aktivnu u biljci i operativno povezanu s nukleotidnom sekvencom koja kodira protein B hemaglutinina (HA) influence u biljku ili dio biljke, pri čemu je izbrisana jedna ili više proteolitičkih petlji proteina HA influence, i
b) inkubaciju biljke ili dijela biljke pod uvjetima koji dopuštaju ekspresiju nukleinskih kiselina, čime se proizvodi VLP.
16. Metoda prema bilo kojem od patentnih zahtjeva 1 – 12 ili 15, pri čemu je transformacija prolazna transformacija.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161541780P | 2011-09-30 | 2011-09-30 | |
| EP12836545.9A EP2760882B1 (en) | 2011-09-30 | 2012-09-28 | Increasing virus-like particle yield in plants |
| PCT/CA2012/050681 WO2013044390A1 (en) | 2011-09-30 | 2012-09-28 | Increasing virus-like particle yield in plants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230695T1 true HRP20230695T1 (hr) | 2023-12-22 |
Family
ID=47994080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230695TT HRP20230695T1 (hr) | 2011-09-30 | 2012-09-28 | Povećanje prinosa virusu sličnih čestica u biljkama |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11155581B2 (hr) |
| EP (2) | EP3626733B1 (hr) |
| JP (1) | JP6248040B2 (hr) |
| KR (1) | KR101974017B1 (hr) |
| CN (2) | CN103930435A (hr) |
| AU (1) | AU2012315421C1 (hr) |
| BR (1) | BR112014007474A2 (hr) |
| CA (1) | CA2850407C (hr) |
| DK (1) | DK2760882T3 (hr) |
| ES (1) | ES2951259T3 (hr) |
| FI (1) | FI2760882T3 (hr) |
| HK (1) | HK1200179A1 (hr) |
| HR (1) | HRP20230695T1 (hr) |
| HU (1) | HUE062759T2 (hr) |
| IL (1) | IL231587B (hr) |
| IN (1) | IN2014CN03077A (hr) |
| MX (2) | MX358883B (hr) |
| MY (1) | MY184072A (hr) |
| NZ (1) | NZ622731A (hr) |
| PL (1) | PL2760882T3 (hr) |
| PT (1) | PT2760882T (hr) |
| RU (1) | RU2682752C2 (hr) |
| SG (2) | SG10201708052XA (hr) |
| SI (1) | SI2760882T1 (hr) |
| TW (1) | TWI700368B (hr) |
| WO (1) | WO2013044390A1 (hr) |
| ZA (1) | ZA201403059B (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11390878B2 (en) | 2011-09-30 | 2022-07-19 | Medicago Inc. | Increasing protein yield in plants |
| WO2013044390A1 (en) | 2011-09-30 | 2013-04-04 | Medicago Inc. | Increasing virus-like particle yield in plants |
| ES2803508T3 (es) | 2013-03-28 | 2021-01-27 | Medicago Inc | Producción de partículas similares al virus de la gripe en plantas |
| BR112016015875A2 (pt) | 2014-01-10 | 2017-09-19 | Medicago Inc | Elementos intensificadores de cpmv |
| WO2015143567A1 (en) | 2014-03-27 | 2015-10-01 | Medicago Inc. | Modified cpmv enhancer elements |
| RU2020132255A (ru) * | 2018-03-14 | 2022-04-15 | Медикаго Инк. | Энхансер экспрессии в растениях |
| CA3103840A1 (en) * | 2018-06-27 | 2020-01-02 | Medicago Inc. | Influenza virus hemagglutinin mutants |
| BR112021017899A2 (pt) * | 2019-03-14 | 2021-12-21 | Medicago Inc | Intensificador de expressão vegetal endógeno |
| WO2021236908A2 (en) * | 2020-05-20 | 2021-11-25 | Biomarin Pharmaceutical Inc. | Use of regulatory proteins for the production of adeno-associated virus |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5428147A (en) | 1983-04-15 | 1995-06-27 | Mycogen Plant Science, Inc. | Octopine T-DNA promoters |
| US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US5100792A (en) | 1984-11-13 | 1992-03-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues |
| US4962028A (en) | 1986-07-09 | 1990-10-09 | Dna Plant Technology Corporation | Plant promotors |
| US5232833A (en) | 1988-09-14 | 1993-08-03 | Stressgen Biotechnologies Corporation | Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants |
| US5805417A (en) | 1995-10-13 | 1998-09-08 | Hitachi, Ltd. | Heat dissipation structure in a portable computer including a heat dissipation block extending from a heat dissipation plate through a first circuit board to a CPU on a second circuit board |
| AU6512299A (en) | 1998-10-07 | 2000-04-26 | Boyce Institute For Plant Research At Cornell University | Gemini virus vectors for gene expression in plants |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| RU2164148C1 (ru) * | 2000-08-09 | 2001-03-20 | Петров Рэм Викторович | Вакцина против вируса гриппа и способ ее получения |
| DE602004028004D1 (de) * | 2003-05-05 | 2010-08-19 | Thompson Boyce Plant Res | Vektoren und zellen zur herstellung von aus transgenen pflanzen gewonnenen immunprotektiven zusammensetzungen |
| CN101123871B (zh) | 2003-05-05 | 2011-05-18 | 美国陶氏益农公司 | 来源于转基因植物细胞的稳定免疫预防性和治疗性组合物及其制备方法 |
| EP1883701B1 (en) * | 2005-04-29 | 2012-01-18 | University of Cape Town | Expression of viral proteins in plants |
| US7871626B2 (en) * | 2005-08-04 | 2011-01-18 | St. Jude Children's Research Hospital | Modified influenza virus for monitoring and improving vaccine efficiency |
| CN103865892B (zh) | 2005-10-18 | 2017-04-12 | 诺瓦瓦克斯股份有限公司 | 功能性流感病毒样颗粒(vlp) |
| WO2007051036A2 (en) * | 2005-10-26 | 2007-05-03 | Protelix, Inc. | Influenza combinatorial antigen vaccine |
| CA2642644A1 (en) | 2006-02-16 | 2007-09-07 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services | Antiviral agents and vaccines against influenza |
| EP2476432B1 (en) | 2006-03-07 | 2015-08-19 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
| WO2008054535A2 (en) | 2006-05-11 | 2008-05-08 | Novavax, Inc. | Novel influenza m2 vaccines |
| CA2651907C (en) | 2006-05-22 | 2016-12-20 | Plant Bioscience Limited | Bipartite system, method and composition for the constitutive and inducible expression of high levels of foreign proteins in plants |
| EP2029167A4 (en) * | 2006-06-16 | 2010-06-16 | Dow Agrosciences Llc | NEW DNA SEQUENCES, VECTORS AND PROTEINS OF BIRD FLUID HEMOGGLUTININE |
| US8697088B2 (en) | 2007-05-25 | 2014-04-15 | Novavax, Inc. | VLPs derived from cells that do not express a viral matrix or core protein |
| WO2008151440A1 (en) | 2007-06-15 | 2008-12-18 | Medicago Inc. | Modifying glycoprotein production in plants |
| CA2615372A1 (en) * | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
| ES2554703T3 (es) * | 2007-11-27 | 2015-12-22 | Medicago Inc. | Partículas recombinantes semejantes al virus de la influenza (VLP) producidas en plantas transgénicas que expresan hemaglutinina |
| GB0800272D0 (en) | 2008-01-08 | 2008-02-13 | Plant Bioscience Ltd | Protein expression systems |
| SG187500A1 (en) | 2008-01-21 | 2013-02-28 | Medicago Inc | Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin |
| PT2294202E (pt) | 2008-07-08 | 2015-10-09 | Medicago Inc | Antigénios gripais recombinantes solúveis |
| MX2011000657A (es) | 2008-07-18 | 2011-03-21 | Medicago Inc | Epitopo de inmunizacion de nuevo virus de la influenza. |
| CA2736796A1 (en) | 2008-08-27 | 2010-03-04 | Arizona Board Of Regents For And On Behalf Of Arizona State University | A dna replicon system for high-level rapid production of vaccines and monoclonal antibody therapeutics in plants |
| EP2413962A1 (en) * | 2009-03-30 | 2012-02-08 | Mount Sinai School of Medicine | Influenza virus vaccines and uses thereof |
| BRPI1015053A2 (pt) | 2009-06-24 | 2019-07-09 | Medicago Inc | partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina |
| FR2947875B1 (fr) | 2009-07-10 | 2011-07-08 | Raymond A & Cie | Dispositif de fixation a elements de fixation multiples dont l'un est flottant |
| WO2011011390A1 (en) | 2009-07-20 | 2011-01-27 | Novavax, Inc. | Purified recombinant influenza virus ha proteins |
| PL2480658T3 (pl) | 2009-09-22 | 2017-12-29 | Medicago Inc. | Sposób otrzymywania VLP pochodzenia roślinnego |
| WO2011102900A1 (en) * | 2010-02-18 | 2011-08-25 | Technovax, Inc. | Universal virus-like particle (vlp) influenza vaccines |
| EP2624864B1 (en) | 2010-10-04 | 2017-12-06 | Massachusetts Institute of Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
| TWI526539B (zh) | 2010-12-22 | 2016-03-21 | 苜蓿股份有限公司 | 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp |
| PL220281B1 (pl) | 2011-09-23 | 2015-09-30 | Inst Biochemii I Biofizyki Polskiej Akademii Nauk | Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciała specyficznie rozpoznające białko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA |
| US11390878B2 (en) * | 2011-09-30 | 2022-07-19 | Medicago Inc. | Increasing protein yield in plants |
| WO2013044390A1 (en) | 2011-09-30 | 2013-04-04 | Medicago Inc. | Increasing virus-like particle yield in plants |
| JP6205359B2 (ja) | 2012-07-23 | 2017-09-27 | 有限会社生物資源研究所 | ワクチン |
| ES2803508T3 (es) | 2013-03-28 | 2021-01-27 | Medicago Inc | Producción de partículas similares al virus de la gripe en plantas |
-
2012
- 2012-09-28 WO PCT/CA2012/050681 patent/WO2013044390A1/en active Application Filing
- 2012-09-28 HR HRP20230695TT patent/HRP20230695T1/hr unknown
- 2012-09-28 CN CN201280047819.2A patent/CN103930435A/zh active Pending
- 2012-09-28 ES ES12836545T patent/ES2951259T3/es active Active
- 2012-09-28 SG SG10201708052XA patent/SG10201708052XA/en unknown
- 2012-09-28 NZ NZ622731A patent/NZ622731A/en unknown
- 2012-09-28 CN CN202310130025.2A patent/CN116218900A/zh active Pending
- 2012-09-28 RU RU2014116371A patent/RU2682752C2/ru active
- 2012-09-28 BR BR112014007474A patent/BR112014007474A2/pt not_active Application Discontinuation
- 2012-09-28 SI SI201232036T patent/SI2760882T1/sl unknown
- 2012-09-28 CA CA2850407A patent/CA2850407C/en active Active
- 2012-09-28 JP JP2014532198A patent/JP6248040B2/ja active Active
- 2012-09-28 MX MX2014003776A patent/MX358883B/es active IP Right Grant
- 2012-09-28 HU HUE12836545A patent/HUE062759T2/hu unknown
- 2012-09-28 FI FIEP12836545.9T patent/FI2760882T3/fi active
- 2012-09-28 PT PT128365459T patent/PT2760882T/pt unknown
- 2012-09-28 PL PL12836545.9T patent/PL2760882T3/pl unknown
- 2012-09-28 DK DK12836545.9T patent/DK2760882T3/da active
- 2012-09-28 KR KR1020147011886A patent/KR101974017B1/ko active IP Right Grant
- 2012-09-28 EP EP19205918.6A patent/EP3626733B1/en active Active
- 2012-09-28 EP EP12836545.9A patent/EP2760882B1/en active Active
- 2012-09-28 SG SG11201400712VA patent/SG11201400712VA/en unknown
- 2012-09-28 MY MYPI2014700716A patent/MY184072A/en unknown
- 2012-09-28 TW TW101135891A patent/TWI700368B/zh active
- 2012-09-28 AU AU2012315421A patent/AU2012315421C1/en active Active
- 2012-09-28 US US14/347,804 patent/US11155581B2/en active Active
- 2012-09-28 IN IN3077CHN2014 patent/IN2014CN03077A/en unknown
-
2014
- 2014-03-19 IL IL231587A patent/IL231587B/en active IP Right Grant
- 2014-03-28 MX MX2018006627A patent/MX2018006627A/es unknown
- 2014-04-29 ZA ZA2014/03059A patent/ZA201403059B/en unknown
-
2015
- 2015-01-21 HK HK15100674.6A patent/HK1200179A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230695T1 (hr) | Povećanje prinosa virusu sličnih čestica u biljkama | |
| Frensing | Defective interfering viruses and their impact on vaccines and viral vectors | |
| RU2015146097A (ru) | Получение вирусоподобных частиц вируса гриппа в растениях | |
| JP2016052331A5 (hr) | ||
| RU2012103038A (ru) | Введение днк в растительные клетки | |
| NZ590144A (en) | Influenza virus-like particles (vlps) comprising hemagglutinin | |
| WO2012083445A8 (en) | Virus like particle production in plants | |
| Zhang et al. | Multiple amino acid substitutions involved in enhanced pathogenicity of LPAI H9N2 in mice | |
| RU2013154698A (ru) | Получение вирусоподобной частицы вируса бешенства в растениях | |
| BR112014012162A2 (pt) | partícula similar a vírus, construto de ácidos nucleicos, vetor, célula hospedeira, vegetal ou tecido vegetal, semente ou progênie do vegetal ou tecido vegetal, composição, métodos para isolar e purificar molécula carregada alvo e para proteger molécula alvo contra hidrólise e processo para purificar partículas similares e vírus | |
| BR112018006984A2 (pt) | planta de soja ou parte da mesma, produto de mercadoria de soja, evento shzd32-01, grânulo, farinha, flocos, ou óleo, métodos para produzir uma planta de soja tolerante a glifosato e para controlar ervas daninhas, e, molécula de dna recombinante. | |
| JP2015517304A5 (hr) | ||
| MX2018001408A (es) | Uso de anexina para para mejorar el rendimiento en condiciones de estres en plantas. | |
| AR107260A1 (es) | Una soja transgénica resistente al glifosato y el método de preparación de la misma | |
| Rota et al. | Molecular virology of the henipaviruses | |
| Cheng et al. | A new distinct geminivirus causes soybean stay-green disease | |
| Urbaniak et al. | In vivo reassortment of influenza viruses. | |
| RU2016132865A (ru) | Энхансерные элементы cpmv | |
| JP7048716B2 (ja) | インフルエンザワクチン用のウイルスシードストックの製造方法、前記シードストックを用いたインフルエンザワクチンの製造方法及び前記方法で製造したウイルスのシードストック | |
| Xiquan et al. | Silencing GhNDR1 and GhMKK2 compromises cotton resistance to Verticillium wilt | |
| WO2013048035A3 (ko) | 마이크로 rna를 이용하여 식물의 환경 스트레스에 대한 내성을 증가시키는 방법 | |
| ZHANG et al. | Detection, Occurrence, and Survey of Rice Stripe and Black-Streaked Dwarf Diseases in Zhejiang Province, China | |
| AR099380A1 (es) | Plantas y constructos relacionados, tolerantes a la sequía y métodos que involucran genes que codifican polipéptidos dtp4 | |
| CN102266389B (zh) | 苦楝皮在制备抑制甲型h1n1流感病毒药物中的应用 | |
| Mallika | sRNA deep sequencing aided plant RNA virus detection in cultivated raspberries and molecular characterization of Raspberry bushy dwarf virus and Black raspberry necrosis virus from Finland |